霍奇金淋巴瘤和非霍奇金淋巴瘤患者红细胞输注需求增加的相关因素

Ali Sheeraz, Ali Mussadique, Badar Farhana, Basit Abdul, Hameed Abdul

J Ayub Med Coll Abbottabad. 2015 Jan-Mar;27(1):70-3.

BACKGROUND

Anaemia is a common feature of lympho-proliferative disorders and is an important cause of poor quality of life in these patients. When indicated, packed red blood cells (PRBC) units are transfused to treat anaemia. Objective of this study was to identify risk factors associated with PRBC transfusions in lymphoma patients.

METHODS

This was a retrospective study done on Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL) patients who had PRBC transfusions during chemotherapy. Information regarding gender, type of lymphoma, stage, baseline haemoglobin, marrow involvement and total number of PRBC units transfused was collected.

RESULTS

A total of 481 patients with diagnosis of HL and NHL were registered during one year period. Out of these, 108 (22.4%) had PRBC transfusions during treatment. HL and NHL patients were 30 (27.8%) and 78 (72.2%) respectively. NHL patients were older than HL (37 vs. 32 years), (p=0.03). HL patients had lower mean haemoglobin 9.3 +/- 2.56 g/dl as compared to NHL 11.33 +/- 2.42 g/dl, (p<0.05). There was significant difference in number of PRBC units transfused based on lymphoma type (NHL 6.74 +/- 5.69 vs. HL 3.97 +/- 3.0 units, p<0.05). Bone marrow involvement resulted in increased transfusion requirements (7.84 +/- 4.36 vs. 5.26 +/- 5.49 units, p<0.05) while stage of disease didn't affected significantly (I/II--4.88 +/- 4.85 and III/IV 6.30 +/- 5.33 units p=0.2).

CONCLUSION

A significant number of lymphoma patients need PRBC transfusions during chemotherapy. NHL patients and bone marrow involvement makes patients at higher risk for transfusions. In places, where blood bank support is not adequate, patients should be informed right from beginning to arrange donors for possible transfusions during chemotherapy.

背景

贫血是淋巴增殖性疾病的常见特征，也是这些患者生活质量低下的重要原因。在有指征时，输注浓缩红细胞（PRBC）单位以治疗贫血。本研究的目的是确定淋巴瘤患者接受PRBC输血的相关危险因素。

方法

这是一项对化疗期间接受PRBC输血的霍奇金淋巴瘤（HL）和非霍奇金淋巴瘤（NHL）患者进行的回顾性研究。收集了有关性别、淋巴瘤类型、分期、基线血红蛋白、骨髓受累情况以及输注的PRBC单位总数的信息。

结果

在一年期间共登记了481例诊断为HL和NHL的患者。其中，108例（22.4%）在治疗期间接受了PRBC输血。HL和NHL患者分别为30例（27.8%）和78例（72.2%）。NHL患者比HL患者年龄大（37岁对32岁），（p = 0.）。HL患者的平均血红蛋白水平为9.3±2.56 g/dl，低于NHL的11.33±2.42 g/dl，（p < 0.05）。根据淋巴瘤类型，输注的PRBC单位数量存在显著差异（NHL为6.74±5.69，HL为3.97±3.0单位，p < 0.05）。骨髓受累导致输血需求增加（7.84±4.36对5.26±5.49单位，p <），而疾病分期没有显著影响（I/II期为4.88±4.85，III/IV期为6.30±5.33单位，p = 0.2）。